ライフサイエンスコーパス: oral dose

1 dose) or a high dose (2.5 times the previous oral dose).

2 erences in study design (e.g., injection vs. oral dosing).

3 te of protection) within 10 days of a single oral dose.

4 ts and cynomolgus monkeys following a single oral dose.

5 ticles (160 individual components) targeting oral dose.

6 ribution of reserpine at 2 h post a 20 mg/kg oral dose.

7 SF Abeta(42) in rats treated with a 30 mg/kg oral dose.

8 be precisely modified in situ with a single oral dose.

9 of 4az for >72 h following a single 10 mg/kg oral dose.

10 uito-killing drug for 10 days after a single oral dose.

11 gh free exposure in mouse following moderate oral doses.

12 ies generally exhibited good efficacy at low oral doses.

13 each cured 3/4 mice with four daily 25 mg/kg oral doses.

14 acitidine exposure increased with escalating oral doses.

15 cid (PFOA), but seen as the result of higher oral doses.

16 m-infected mice, providing a cure after four oral doses.

17 tumor growth inhibition at 50 mg/kg QD upon oral dosing.

18 achieved good pharmacokinetics in dogs with oral dosing.

19 tagonism in several in vivo models following oral dosing.

20 e demonstrated exposure in animals following oral dosing.

21 idence for tumor growth inhibition following oral dosing.

22 amyloid-beta (Abeta) in the CNS after acute oral dosing.

23 potency and good brain penetration following oral dosing.

24 nflammatory and neuropathic pain models upon oral dosing.

25 xposure in rat pharmacokinetic studies after oral dosing.

26 y improved by administration of TTT-3002 via oral dosing.

27 th vaginal dosing and only 19% of women with oral dosing.

28 d in vivo bioavailability after either iv or oral dosing.

29 om the androgenic activity on prostate after oral dosing.

30 The same effect could not be achieved by oral dosing.

31 ta-amyloid peptides in mouse brain following oral dosing.

32 e (Abeta) levels in wild-type rats following oral dosing.

33 compounds with prolonged exposure following oral dosing.

34 s dose dependent and supported twice per day oral dosing.

35 r activity, and rat liver exposure following oral dosing.

36 active triphosphate species following single oral dosing.

37 vage fluid in allergen-challenged mice after oral dosing.

38 RO4929097 is active following oral dosing.

39 n a lymphoma xenograft mouse model following oral dosing.

40 and occurring at concentrations relevant to oral dosing.

41 serum RBP4 levels by >80% in mice upon acute oral dosing.

42 wing for clinically relevant exposures after oral dosing.

43 d total cholesterol levels in rats following oral dosing.

44 for its use is sparse and limited to use of oral dosing.

45 show robust in vivo target engagement after oral dosing.

46 onstrated anticoagulant effects at 2 h after oral dosing (100 mg.kg(-1)), with a significant 43% prol

47 ction of brain Abeta was 40-50%, 1.5 h after oral dosing (100 mumol/kg).

48 Single doses (0.25 to 100 mg) and repeated oral doses (2.5 to 20 mg for 10 days) of BIA 10-2474 had

49 d 15 healthy women (controls) given a single oral dose (20 mg or 200 mg) of the CRF-R1 antagonist or

50 vax malaria received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg).

51 In rat models, a single oral dose (200 mug/kg) of EL-CSG showed a relative oral

52 lthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.

53 and one following administration of a single oral dose (60 mg) of methylphenidate.

54 was also curative in this model in a single oral dose (80 mg/kg).

55 man pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PAR

56 s, mice were given 5 transdermal doses and 5 oral doses administered alternatively, beginning with tr

57 on of their antimalarial efficacy via single oral dose administration in two 60-day survival studies

58 d circulating reticulocytes following single oral dose administration, while 4-week q.d. po administr

59 Relationships between oral dose and biomarker concentrations were assessed usi

60 file was sustained up to 24 h after a single oral dose and did not impair the functions of the immune

61 ixaban differ from warfarin with their fixed oral dose and no requirement for routine monitoring.

62 .4% after administration of 100 mg/kg single oral dose and prolonged mice survival by an average of 1

63 stently positive linear relationship between oral dose and urinary concentration was observed (R2 > 0

64 ty compared with clopidogrel before the next oral dose and, although platelet reactivity was lower wi

65 With 300-400 mg twice-daily oral doses and 200-300 mg twice-daily intravenous doses,

66 t exposure protocols were used: single daily oral doses and continuous exposure via subdermal implant

67 awley rats highlighted a good exposure after oral dosing and a minimum brain penetration.

68 Oral dosing and brain activity of 5b were established in

69 nce therapy given its convenient once-weekly oral dosing and low toxicity profile.

70 vity vs S1P3 receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for p

71 Abeta levels in rat CSF and brain following oral dosing, and compound 37 exhibited an improved cardi

72 GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repress

73 strated in vivo tumor growth inhibition upon oral dosing, and was selected for preclinical evaluation

74 significantly CSF Abeta40 and 42 in rats at oral doses as low as 1 mg/kg.

75 iting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) stu

76 n July 2014 and is recommended to infants as oral doses at ages 6 and 10 weeks.

77 ion, and elicited 100% animal survival after oral dosing at 25 mg/kg b.i.d. for 5 and 15 days.

78 nic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse.

79 antly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p < 0.05) and a

80 drogenic activity on ventral prostate, after oral dosing at 30 mg/kg.

81 i infected mice in 3/6 derivatives following oral dosing at 4 x 30 mg/kg, with microsomal metabolic s

82 An oral dose, at 200mg/kg/day, resulted in significant decl

83 asured in the fasted state with high and low oral doses, before and after parenteral replenishment of

84 TAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable sy

85 study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma cle

86 t radioprotection in mice at single nontoxic oral dose by a dose-reduction factor of 1.28.

87 rd-trimester fetuses exposed to single daily oral doses during the time of follicle formation reveale

88 imus was administered alone as a single 2-mg oral dose, followed by a minimum 14-day washout period,

89 ne was administered alone as a single 100-mg oral dose, followed by a minimum 8-day washout period, a

90 ous hydrocortisone equivalent to presurgical oral dosing, followed by taper).

91 We aimed to examine a range of oral doses for safety, tolerability, and efficacy for th

92 ablished T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7

93 and reverse toxicokinetics, to obtain human oral dose hazard values that are similar to published ma

94 as protect at-risk populations with a single oral dose, highlighting the strength of diversity-orient

95 f B16 melanoma tumors in mice at a tolerated oral dose in a T cell-dependent manner but had little ef

96 ned with high potency led to a predicted low oral dose in humans.

97 ed with high potency, led to a predicted low oral dose in humans.

98 ntrolled, randomized trial evaluating single oral doses in healthy adult males.

99 d 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test.

100 issolution rate-limited absorption following oral dosing in humans.

101 tional downstream effector (p70S6) following oral dosing in mice.

102 hed that 13-d had properties compatible with oral dosing in mouse models of disease (Fpo 49%).

103 rtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection.

104 Following oral dosing in rats for 7 days, salbutamol and triflusal

105 Upon oral dosing in rats, CAGE increased peak blood concentra

106 d compared to in vivo performance, following oral dosing in rats.

107 essfully reducing brain Htt levels following oral dosing in rats.

108 ions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. fal

109 A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic

110 calcium ionophore-stimulated rat model after oral dosing (in vivo, IC(50,free) = 34 nM).

111 The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbe

112 t target engagement in mouse liver following oral dosing, leading to improved lipid metabolism and in

113 dels of type 2 diabetes revealed that single oral doses lowered hyperglycemia within 60 min, enhanced

114 ellent solubility at low pH, suggesting that oral dosing may be possible.

115 Comparison with the oral doses obtained when flies were fed an IMI-sucrose m

116 the second night, 1 group received a single oral dose of 0.25mg pramipexole, whereas a second group

117 iod, all of the subjects received a one-time oral dose of 0.5 mg trans-resveratrol/kg body weight in

118 le, whereas a second group received a single oral dose of 0.5mg clonazepam, and the remaining patient

119 nd demonstrated 50% receptor occupancy at an oral dose of 0.8 mg/kg in rats and an intravenous dose o

120 ompound 18 proved to be useful, which at low oral dose of 1 (mg/kg)/day body weight increased bone ma

121 olesteryl ester (CE) transfer activity at an oral dose of 1 mg/kg in human CETP/apoB-100 dual transge

122 Single oral dose of 10 mg of dexamethasone (n = 293) or identic

123 plasma viral loads were administered a daily oral dose of 10 mg/kg for 35 days.

124 In healthy adults (n=4), 2 hr after a single oral dose of 10-mg TAC, the p38 MAPK activation was inhi

125 We then administered either cortisol (single oral dose of 100 mg hydrocortisone, N = 34) or testoster

126 randomly assigned to receive either a bolus oral dose of 100,000 IU cholecalciferol followed by 4000

127 ned in a 1:1:1 ratio to receive a once-daily oral dose of 1500 mg of voxelotor, 900 mg of voxelotor,

128 mpare the antisecretory response to a single oral dose of 20 mg rabeprazole, 20 mg omeprazole and pla

129 ndomly assigned to receive either an initial oral dose of 200 000 IU (5.0 mg) colecalciferol (vitamin

130 , participants were randomized to an initial oral dose of 200 000 IU vitamin D3 followed by 100 000 I

131 , participants were randomized to an initial oral dose of 200,000 IU vitamin D3 followed by 100,000 I

132 All children received one oral dose of 30 mg/kg azithromycin.

133 asmodium berghei-infected mice with a single oral dose of 30 mg/kg.

134 were screened for their response to a single oral dose of 325-mg immediate release or enteric coated

135 rated male Holstein calves received a single oral dose of 35 g of IH to achieve a target dose of 5.4

136 Each participant consumed a single oral dose of 35 mg (13)C-EPA and its metabolism was foll

137 omparison of DPS and plasma was made (single oral dose of 37.5 mg of paroxetine).

138 ce, compound 4 was completely curative at an oral dose of 4 x 10 mg/kg.

139 vival days of 12 and 14, respectively, at an oral dose of 4 x 50 mg/kg.

140 ere performed, each with the use of a single oral dose of 40 mg (13)C-DHA.

141 Following an oral dose of 40 mg/kg/day for 30 days, quinacrine concen

142 ministration of a standard treatment (single oral dose of 400 mg albendazole).

143 One group was given an oral dose of 45 mg zinc/d as a gluconate for 6 mo.

144 rticipants in both groups in a daily divided oral dose of 45 mg/m(2) until remission, or until day 60

145 lation (TMS) to test the effects of a single oral dose of 50 and 100 mg of S44819 on electromyographi

146 8 d, the same participants consumed a single oral dose of 50 mg (13)C-AA and its metabolism was follo

147 nced 2 h (peak plasma levels) after a single oral dose of 600 mg CBD or placebo.

148 n metastatic melanoma patients treated at an oral dose of 960 mg twice daily.

149 A single oral dose of [(14)C]metformin was administered to C57BL/

150 A prophylactic oral dose of a FimH small-molecular-weight antagonist (Z

151 In this approach, patients receive an oral dose of a fluorescent contrast agent and a fibre-op

152 However, 1 oral dose of a small-molecular-weight compound that inhi

153 eriment 1, we tested the effects of a single oral dose of alprazolam (a classical benzodiazepine acti

154 and PCR conversion to HD negative, a single oral dose of azithromycin is efficacious for the treatme

155 302 of 16,092 residents (82.7%) received one oral dose of azithromycin.

156 In contrast, only 77% of the oral dose of BPA was absorbed and underwent an extensive

157 The effects of a single oral dose of cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-

158 A single oral dose of compound 11a resulted in a significant redu

159 An oral dose of CsA was administered to 24 healthy voluntee

160 ubsequent coadministration of a single 10-mg oral dose of cyclosporine with either a single dose of t

161 C]CIMBI-36 PET scans before and 3 h after an oral dose of d-amphetamine (0.5 mg/kg).

162 ntanil PET before and 3 hours after a single oral dose of d-amphetamine (either a "high" dose, .5 mg/

163 Humans treated with a single oral dose of DADMe-ImmH in phase 1 clinical trials exhib

164 one before and one 3 h following a 0.5 mg/kg oral dose of dexamphetamine to measure baseline MOR avai

165 ry duct-ligated (BDL) rats received a single oral dose of droxidopa (25-50 mg/kg) or vehicle and hemo

166 Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D(3) or placebo

167 th fMRI twice, one month apart, following an oral dose of either delta-9-THC (10 mg) or placebo, whil

168 diet) and treated on postnatal day 4 with an oral dose of either VA (6 mug retinyl palmitate/g body w

169 This trial shows that a single oral dose of encapsulated glutamine can promote increase

170 Following a single oral dose of gefitinib (50 or 150 mg/kg), tumors were pr

171 ants were randomized 1:1:1:1 to a once-daily oral dose of GSK1278863 (0.5 mg, 2 mg, or 5 mg) or contr

172 nal receptor binding (VT) following a single oral dose of GSK598809 (60 mg) were consistent with thos

173 Participants were treated with a single oral dose of IDA (ivermectin, 200 mug/kg; diethylcarbama

174 A time course simulation following an oral dose of iron was compared to a clinical time course

175 onsecutive dosing panels, receiving a single oral dose of islatravir (0.5-30 mg).

176 s 4-6 h after the administration of a single oral dose of JNJ-54175446 (dose range, 5-300 mg).

177 Animals were given a single oral dose of KBrO(3) (100mg/kg body weight) and sacrific

178 The renal effects of single oral dose of KBrO(3) appeared to be reversible; maximum

179 thy participants were randomised to a single oral dose of losartan (50 mg) or placebo, 1 h before bei

180 ed the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy

181 ting the pharmacodynamic effects of a single oral dose of NDI-010976 on hepatic DNL in overweight and

182 etics and function before and after a single oral dose of nicotinic acid using cardiac MRI to demonst

183 ) can rise as much as 2.7-fold with a single oral dose of NR in a pilot study of one individual, and

184 ehavioural impact of informing smokers their oral dose of NRT is tailored to analysis of DNA.

185 Informing smokers their oral dose of NRT was tailored to genotype not phenotype

186 At a much lower single oral dose of only 54 mg/kg combined with 13 mg/kg of mef

187 Upon receiving a single oral dose of only 6 mg/kg of the monomeric trioxane 12c

188 time course of 25 h after intake of a single oral dose of phentermine.

189 betic fatty (ZDF) rats 45 min after a single oral dose of pioglitazone (30 mg/kg).

190 ed, and the pharmacokinetics (PK) of a 30-mg oral dose of PQ was measured in 45 volunteers.

191 A single oral dose of propranolol (40 mg) significantly increased

192 Subsequent evaluation revealed that a single oral dose of purified, soluble CFA/I fimbriae protected

193 cacy documented 10 days and 3 months after 1 oral dose of PXVX0200 supports further development as a

194 Remarkably, a single oral dose of SAR405838 is sufficient to achieve complete

195 bolism in humans and mice following a single oral dose of saturated fat.

196 Meanwhile, a single oral dose of shizukaol F reduced gluconeogenesis in C57B

197 fraction, 60 +/- 14%) who received a single oral dose of sildenafil (40 or 80 mg).

198 ntral macula at 1 and 3 hours after a 100 mg oral dose of sildenafil citrate.

199 n healthy volunteers in response to a single oral dose of sitagliptin.

200 sign and all participants ingested either an oral dose of synthetic THC (n=41) or placebo (n=37) befo

201 A single oral dose of tafenoquine leads to high efficacy against

202 An oral dose of TD or GP of SM was administrated to subject

203 afety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combinati

204 ch visit they received either a single 20-mg oral dose of the selective serotonin reuptake inhibitor

205 o treatment groups who received at least one oral dose of tosedostat.

206 ld, were randomly allocated 1:1 to receive 1 oral dose of vaccine (approximately 5 x 10(8) colony-for

207 1:1) participants to receive either a single oral dose of vaccine or placebo.

208 y assigned (ratio 1:1) to receive either one oral dose of vitamin A (50,000 IU) or placebo immediatel

209 hy volunteers, supplementation with a single oral dose of vitamin D (100,000 IU vitamin D2) increased

210 netic approach in 40 volunteers who received oral doses of 0.5 mg digoxin.

211 Oral doses of 0.5 or 2.0 g SRT2104 or matching placebo w

212 moderate activity when administered as four oral doses of 100 mg kg(-1).

213 ties (October 2012-July 2013) compared daily oral doses of 100 mg of pritelivir with 500 mg of valacy

214 namic studies in APP51/16 transgenic mice at oral doses of 180 mumol/kg demonstrated significant redu

215 t with diet-induced obesity following single oral doses of 3 and 10 mg/kg.

216 Patients were randomized (1:1:1) to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, o

217 3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in

218 etermine whether the 25(OH)D response to six oral doses of 3 mg vitamin D(3), administered over 1 yea

219 ents were allocated to receive six 2-monthly oral doses of 3 mg vitamin D3 or placebo over 1 year in

220 (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.

221 re randomly assigned (3:1) to receive single oral doses of ABI-H0731 (100, 300, 600, or 1000 mg) or m

222 Participants received oral doses of abiraterone acetate (1000 mg daily) and pr

223 althy adults, physicians tend to assume that oral doses of acetaminophen will be completely absorbed

224 We administered various oral doses of alectinib (300-900 mg twice a day) during

225 atio to receive either two directly observed oral doses of cholecalciferol (300,000 IU) or matching p

226 cted patients after administration of single oral doses of DCV.

227 re assigned to cohorts to receive escalating oral doses of decitabine and cedazuridine.

228 Patients received oral doses of enasidenib at 60-300 mg per day in repeate

229 ere at least 90 cm in height received single oral doses of ivermectin (150-200 mug/kg) and albendazol

230 ject Monte Carlo experiments to identify the oral doses of linezolid, moxifloxacin, and faropenem tha

231 u(1 + 2) were observed in patients receiving oral doses of MTX, whereas higher concentrations of MTXG

232 ment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart)

233 We conducted a phase 2 trial of 2 oral doses of solithromycin (1200 and 1000 mg) for treat

234 The effects on behavior of daily oral doses of sulforaphane (50-150 micromol) for 18 wk,

235 ious treatment status, to receive once-daily oral doses of tenofovir alafenamide 25 mg or tenofovir d

236 Remarkably, pretreatment with just 2 oral doses of the BTKi acalabrutinib completely prevente

237 lymphopoietin (TSLP) and antigen to repeated oral doses of the same antigen induced acute diarrhea an

238 dent study examined the relationship between oral doses of three widely used personal care product in

239 ~TLZ conjugate was as effective as ~30 daily oral doses of TLZ in growth suppression of homologous re

240 HV-infected woodchucks received eight weekly oral doses of vehicle, 1 mg/kg GS-9688, or 3 mg/kg GS-96

241 al study NP22657 (BRIM-2), patients received oral doses of vemurafenib (960 mg twice per day).

242 Oral dosing of 2 or 4 yielded a dose-dependent decrease

243 mRNA induction (2.7-fold over vehicle) upon oral dosing of 27 at 300 mg/kg.

244 ood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

245 reductions in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376.

246 Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt

247 Oral dosing of compound 2 to mice resulted in a dose-dep

248 t numerous studies showed efficacy following oral dosing of cordycepin, we found that intact cordycep

249 Twice-daily oral dosing of delamanid at 30 mg kg(-1) for 5 days resu

250 , photodynamic therapy, topical dorzolamide, oral dosing of eplerenone or acetazolamide, or some comb

251 Oral dosing of EZM2302 demonstrates dose-dependent in vi

252 Oral dosing of GLPG0634 in a therapeutic set-up in a col

253 xide (2H2O), whereas egg was labeled through oral dosing of hens with a uniformly 2H-labeled amino ac

254 pendent inhibition in wild-type mice through oral dosing of JNJ-54271074.

255 In a mouse PK/PD model, oral dosing of lead compound 2 demonstrated dose-depende

256 Once daily oral dosing of LY2940094 at 40 mg for 8 weeks vs placebo

257 Oral dosing of PRCL-02 was well tolerated and resulted i

258 In addition, after oral dosing of several phosphoramidate derivatives of co

259 In vivo PCSK9 lowering by oral dosing of the candidate prodrug and quantification

260 Oral dosing of these compounds in diabetic mice induces

261 ransplant model is significantly improved by oral dosing of TTT-3002.

262 The effects of a lethal APAP oral dose on methemoglobin (MetHb, non-oxygen carrying f

263 , respectively, thus providing an attractive oral dosing option that does not require routine laborat

264 w dose (equivalent to the patient's previous oral dose) or a high dose (2.5 times the previous oral d

265 ids intravenously for 1 week then a tapering oral dose over 8 weeks.

266 vaginal dosing were 56-fold lower than after oral dosing (p<0.001).

267 >/=130-fold higher with vaginal compared to oral dosing (p<0.001).

268 and theoretically greater PrEP efficacy than oral dosing; randomized topical dosing PrEP trials to th

269 dipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol production by 85% following a

270 ange, 11.3 to 37.6), supporting a once-daily oral dosing regimen.

271 Oral dosing renders blood stage parasitaemia undetectabl

272 mately 100- and 40-fold lower than after TFV oral dosing, respectively).

273 a broad range of plasma concentrations after oral dosing resulted from small structural changes to th

274 ersion to an acetate prodrug 25b, which upon oral dosing resulted in an improved pharmacokinetic prof

275 a of the control group treated with the same oral dose rose to higher levels for 6-7 hours but then d

276 harmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phospho

277 Adding a glucose tracer to the oral dose significantly enhances the assessment of insul

278 n uninflamed prostate following a single 3-g oral dose, such that it may be a potential option for pr

279 e against both stages in vivo, with a single oral dose sufficient to clear liver stage infection.

280 -dose for acute treatment of migraine at all oral doses tested.

281 al blood mononuclear cells (PBMCs) following oral dosing, TFV-DP levels in vaginal lymphocytes decrea

282 After a single oral dose, the mean +/- SD maximal concentration of thia

283 In order to obtain a more stable form for oral dosing, the sulfhydryl group in conjugate 1 was con

284 w compounds administered at single 100 mg/kg oral doses to F. hepatica infected rats, 8 had statistic

285 the importance of carefully considering the oral dose used in animal experiments and provides useful

286 Compared to oral dosing, vaginal dosing achieved much lower serum co

287 The data indicated that almost all the BPS oral dose was absorbed and transported into the liver wh

288 ls, while decreased phosphoproteins after 7d oral dosing was consistent with V565-TNFalpha engagement

289 gnalling proteins in biopsies taken after 7d oral dosing was decreased by approximately 50%.

290 y with good overall drug-like properties for oral dosing, was well tolerated across preclinical speci

291 sly on day 1 and were permitted to switch to oral dosing when clinically indicated.

292 and pharmacokinetic parameters suitable for oral dosing, which led to the discovery of (2R)-1-[4-(4-

293 cy and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory

294 The antiviral efficacy of weekly oral dosing with 3 mg/kg GS-9688 was confirmed in a seco

295 icipants were assigned to receive 3 weeks of oral dosing with placebo or fluoxetine, 40 mg per day.

296 (HFD) to mice for 10 weeks, followed by five oral dosing with purified AHC or ovalbumin on alternate

297 Moreover, oral dosing with the Mnk inhibitor significantly suppres

298 Oral dosing with Wy14643 similarly induced Hilpda mRNA l

299 SK2801 had reasonable in vivo exposure after oral dosing, with modest clearance and reasonable plasma

300 duced CBF (using indomethacin [1.2 mg kg(-1) oral dose]) would impair cognition in young (n = 13; 25